StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NEPHROPLUS.BO$636.60-1.52%
Fair $636.60+0.0%

NEPHROPLUS.BO

NEPHROPLUS.BO

Healthcare / Medical Care FacilitiesBSE

$636.60

-9.20 (-1.52%)

Fairly Valued+0.0%Fair Value $636.60Fund rank 30/100 · Data gapFallback financials|
SA 62/B
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $345.5M · quality 53.3/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 24/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

62/100

B

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · NEPHROPLUS.BOLocal privado en este navegador · NEPHROPLUS.BO
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$63.9B

P/E

78.4x

↑

EV/EBITDA

24.1x

↑

ROE

6.9%

↑

Gross Margin

40.9%

↓

Debt/Equity

0.07

↓
52-Week Range$637
$445$662

TradingView lightweight chart

NEPHROPLUS.BO price, volumen y niveles de valoración

Último $596.80Periodo +26.5%
Fair value: $636.60

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+34.1%

FCF CAGR

—

FCF margin

11.3%

FCF / Net income

1.47x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $9.99B · net income $768.4M · FCF $1.13B

2023-FY → 2026-FY

Gross margin

40.9%+15.9% pts

Operating margin

13.6%+12.8% pts

Net margin

7.7%+10.5% pts

FCF margin

11.3%+26.4% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$9.99B$9.99B$7.56B$5.40B$4.15B
Net Income$768.4M$768.4M$671.0M$351.3M$-117.9M
EBITDA$2.48B$2.48B$1.81B$1.07B$528.7M
EPS8.108.106.693.50-1.17
Gross Margin40.9%40.9%37.2%31.7%25.0%
Operating Margin13.6%13.6%12.5%9.9%0.9%
Net Margin7.7%7.7%8.9%6.5%-2.8%
Balance Sheet
Debt/Equity0.070.070.440.650.55
Current Ratio2.802.80———
Cash Flow
Free Cash Flow$1.13B$1.13B$345.5M$-77.2M$-624.7M
Returns
ROE6.9%6.9%11.5%8.5%-3.0%
Valuation
P/E78.4078.40———
EV/EBITDA24.1424.14———
P/B5.415.41———
Growth & Yield
Revenue Growth32.2%32.2%40.1%30.2%—
EPS Growth21.1%21.1%91.0%398.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

91.1%

muy exigente

EPS terminal req.

$56.49

Spread vs growth

-69.9%

5Y implied EPS CAGR

53.2%

muy exigente

EPS terminal req.

$68.35

Spread vs growth

-32.1%

10Y implied EPS CAGR

29.8%

muy exigente

EPS terminal req.

$110.08

Spread vs growth

-8.7%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +26.5%

Total return

+26.5%

Start / end P/E

70.5x → 73.7x

EPS bridge

6.69 → 8.10

Residual

+0.9%

EPS growth+21.1%
Multiple rerating+4.5%
Dividend+0.0%
Residual / FX / buybacks / cross-term+0.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.